Neeraj Agarwal: Intensification and de-intensification in treatment of mRCC by Sumanta K. Pal at IUCS24

Neeraj Agarwal shared on X:

“Intensification and de-intensification in treatment of mRCC kidney cancer.

Fantastic talk by the master Sumanta K. Pal at IUCS24.

His take on adjuvant and ph3 trials and de-intensification of Treatment with microbiome modulation.”

Source: Neeraj Agarwal/X

More posts featurnig Neeraj Agarwal on oncodaily.com

Neeraj Agarwal is a Professor of Medicine, and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program, and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is an Advisor to the Oncology Drug Advisory Committee and the United States Food and Drug Administration, leads early therapeutics in the SWOG genitourinary cancers committee, and is the Chief Editor of ASCO Daily News.

Sumanta (Monty) Pal, MD, is a medical oncologist and an expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center in Los Angeles. He serves as the Vice Chair of Academic Affairs, Professor and co-director of the Kidney Cancer Program and leads the Kidney and Bladder Cancer Disease Team at City of Hope. He specialises in kidney, bladder, and prostate cancers.